EUVIMEDEUVIMED entdecken
Multizentrische Studie

Patterns of response and survival in metastatic paragangliomas and pheochromocytomas: Experience from two Spanish neuroendocrine tumor centers

M I Del Olmo-García, J E Contreras Saldarriaga, L Hernandez-Rienda, J Hernando-Cubero, A García Alvarez, A García-Burillo iD, A Casterás, A Segura-Huerta, S Prado, R Palasí, J F Merino-Torres, J Capdevila Castillón

Journal of Neuroendocrinology · 2026-04 · 38 (4)

DOI: 10.1111/jne.70175 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 03.04.2026. Verfasst von M I Del Olmo-García und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Nutrition, University and Polytechnic Hospital La Fe, Valencia, Spain. Hauptthemen laut MEDLINE: Paraganglioma, Pheochromocytoma, Adrenal Gland Neoplasms, Neuroendocrine Tumors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic pheochromocytomas and paragangliomas (mPPGLs) are uncommon, heterogeneous neuroendocrine tumors lacking standardized systemic treatment pathways. Evidence on treatment response predictors and outcome‐based stratification remains limited. We conducted a retrospective study of 49 patients with mPPGLs treated between 2010 and 2024 at two Spanish referral centers. We evaluated clinical characteristics, systemic treatment patterns, radiologic responses (per RECIST), and survival outcomes. Patients were stratified into five clinical evolution patterns based on treatment response and disease trajectory. The most common indications for initiating systemic therapy were radiologic progression (59.5%) and high tumor burden (31%). First‐line treatments included somatostatin analogues (SSAs, 40.5%), radionuclide therapies (33.3%: 177 Lu 9.5% and 131 I‐MIBG 23.8%), and chemotherapy (23.8%). Partial response rates were higher with chemotherapy, 131 I‐MIBG, and 177 Lu compared with SSAs. Tumor burden at treatment initiation appeared to be more closely associated with radiologic response than radiologic progression. Progression‐free survival (PFS) appeared to differ according to first‐line treatment type, with longer PFS observed in patients receiving radionuclide therapies. The median overall survival from systemic treatment initiation was 48 months. Five clinical evolution patterns were identified, highlighting disease heterogeneity. Radiologic progression remains the main trigger for systemic treatment in mPPGLs; however, initial tumor burden appears to be a stronger predictor of treatment response. Our proposed five‐pattern clinical classification may contribute to prognostication and therapeutic individualization. Prospective studies are a key unmet need to determine the optimal timing and sequencing of systemic therapies in mPPGL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ParagangliomaPheochromocytomaAdrenal Gland NeoplasmsNeuroendocrine TumorsHumansFemaleSpainMaleRetrospective StudiesMiddle AgedAdultAgedTreatment Outcome

Stichwörter der Autor:innen

metastatic paragangliomapheochromocytomaradionuclide therapysystemic treatmenttumor burden

Autor:innen und Institutionen

  • Department of Endocrinology and Nutrition, University and Polytechnic Hospital La Fe, Valencia, Spain.
  • Joint Research Unit on Endocrinology, Nutrition and Clinical Dietetics, University of Valencia-Health Research Institute La Fe, Valencia, Spain.
  • Department of Medicine, Faculty of Medicine, University of Valencia, Valencia, Spain.
  • Universidad de Antioquia, Departamento de Endocrinología, Facultad de Medicina, La Candelaria, Medellín, Antioquia, Colombia.
  • Department of Oncology, Hospital Universitario Vall Hebron y VHIO-Vall Hebron Instituto de Oncologia, Barcelona, Spain.
  • Department of Nuclear Medicine, Hospital Universitario Vall Hebron y VHIO-Vall Hebron Instituto de Oncologia, Barcelona, Spain.

ORCID-Profile: A García-Burillo

Zitieren

APA

Del Olmo-García, M. I., Contreras Saldarriaga, J. E., Hernandez-Rienda, L., Hernando-Cubero, J., García Alvarez, A., García-Burillo, A., Casterás, A., Segura-Huerta, A., Prado, S., Palasí, R., Merino-Torres, J. F., & Capdevila Castillón, J. (2026). Patterns of response and survival in metastatic paragangliomas and pheochromocytomas: Experience from two Spanish neuroendocrine tumor centers. Journal of Neuroendocrinology, 38(4). https://doi.org/10.1111/jne.70175

Vancouver

Del Olmo-García MI, Contreras Saldarriaga JE, Hernandez-Rienda L, Hernando-Cubero J, García Alvarez A, García-Burillo A, et al. Patterns of response and survival in metastatic paragangliomas and pheochromocytomas: Experience from two Spanish neuroendocrine tumor centers. Journal of Neuroendocrinology. 2026;38(4). doi:10.1111/jne.70175

BibTeX
@article{DelOlmoGarca2026,
  author = {Del Olmo-García, M I and Contreras Saldarriaga, J E and Hernandez-Rienda, L and Hernando-Cubero, J and García Alvarez, A and García-Burillo, A and Casterás, A and Segura-Huerta, A and Prado, S and Palasí, R and Merino-Torres, J F and Capdevila Castillón, J},
  title = {Patterns of response and survival in metastatic paragangliomas and pheochromocytomas: Experience from two Spanish neuroendocrine tumor centers},
  journal = {Journal of Neuroendocrinology},
  year = {2026},
  volume = {38},
  number = {4},
  doi = {10.1111/jne.70175}
}
Kostenlos starten →